STOCK TITAN

Twist Bioscience - TWST STOCK NEWS

Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.

Twist Bioscience Corporation (TWST) is a pioneering company in the field of synthetic biology, specializing in the industrial-scale production of synthetic DNA. At the heart of its operations is a proprietary semiconductor-based DNA synthesis platform, which represents a significant advancement over traditional methods. By synthesizing DNA on a 10,000-well silicon platform instead of conventional 96-well plastic plates, Twist Bioscience achieves unprecedented levels of efficiency, scalability, and cost-effectiveness. This innovation enables the production of high-quality synthetic DNA at a faster pace and lower cost, addressing key inefficiencies in the industry.

The company's product offerings include a wide range of synthetic biology tools such as oligonucleotides, genes, pathways, chassis, and genomes. These tools are critical for applications across multiple industries, including pharmaceutical research, personalized medicine, agriculture, sustainable chemical production, and emerging fields like DNA data storage and in vivo diagnostics. Twist Bioscience's platform not only accelerates research and development but also empowers organizations to innovate in areas such as biodetection and bioengineering.

Operating primarily in the United States, Twist Bioscience serves a diverse customer base that includes biotech firms, pharmaceutical companies, academic institutions, and industrial research organizations. Its business model revolves around direct sales of synthetic DNA products and services, catering to the growing demand for advanced biological engineering solutions. By leveraging its cutting-edge technology, the company has established itself as a critical enabler in the synthetic biology ecosystem.

The broader synthetic biology industry is characterized by rapid innovation and significant growth potential, driven by advancements in genomics, bioinformatics, and sustainable technologies. Twist Bioscience's focus on high-throughput, cost-effective DNA synthesis positions it as a key player in this dynamic market. However, the company faces competition from other DNA synthesis providers, necessitating continuous investment in research and development to maintain its technological edge.

What sets Twist Bioscience apart is its commitment to overcoming traditional limitations in DNA synthesis. By utilizing silicon-based manufacturing, the company not only enhances production efficiency but also expands the possibilities for synthetic biology applications. This unique approach underscores its role as a transformative force in the industry, enabling researchers and organizations to unlock new opportunities in science and technology.

In summary, Twist Bioscience combines technological innovation with a deep understanding of synthetic biology to deliver high-quality DNA synthesis solutions. Its proprietary platform and diverse product offerings make it a vital partner for industries seeking to harness the power of engineered biology. As the demand for synthetic DNA continues to grow, Twist Bioscience remains at the forefront of enabling groundbreaking advancements across multiple sectors.

Rhea-AI Summary
Twist Bioscience (NASDAQ: TWST) launches a new Human Pangenome Spike-in for the Twist Exome 2.0 panel to enhance genetic variation detection during whole exome sequencing. The tool aims to provide a more comprehensive view of human genetic diversity, leveraging the Human Pangenome Reference Consortium's diverse genomic data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announces CE-marked Precision Dx Products compliant with EU IVDR regulations, including Twist Precision Prep and Enrichment Dx Kit, Twist Precision Exome Dx Panel, and Twist Precision Exome Dx Kit. The products aim to facilitate panel sequencing within clinical settings, meeting high quality standards. Twist collaborates with Platomics to streamline documentation generation and regulatory compliance. CEO Emily M. Leproust highlights the significance of IVDR certification for diagnostic tests and the company's commitment to supporting European customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) executives will participate in fireside chats at upcoming investor conferences, including TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference. The chats will be webcast live and available for replay for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
conferences
Rhea-AI Summary
Twist Bioscience Corporation (TWST) announced the grant of 122,400 restricted stock units (RSUs) to 36 recently hired individuals as an employment inducement. The RSUs vest over a 48-month period, with 25% vesting on the one year anniversary of the start date of the employee, and 1/16 of the RSUs vesting on each quarterly anniversary thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) and Element Biosciences, Inc. announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System. The collaboration aims to offer customers an economical and streamlined approach to next generation sequencing. The Exome 2.0 panel and high performing library preparation and target enrichment reagents are designed to provide best-in-class sequencing, detect rare and inherited diseases, and germline cancers. The purpose-built solution for Element’s AVITI chemistry will reduce per sample sequencing requirements, potentially saving downstream sequencing costs. The companies have ambitious product roadmaps for 2024 to make sequencing even easier for labs to produce the highest quality data at a low cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (TWST) has launched the cfDNA Library Preparation Kit to enable liquid biopsy research, addressing challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input. The kit can detect rare allele variants due to its high conversion rate and protocols minimize sample handling for a streamlined workflow and results delivered within two hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) announced the early access of the Twist Flex Prep Ultra High-Throughput (UHT) Kit, a novel technology that aims to enable unparalleled throughput at a fraction of the cost of existing on-market solutions. The kit utilizes novel chemistry that accepts and self-normalizes a wide range of sample input amounts through a new proprietary Normalization By Ligation (NBL) technology, crucial for researchers in AgBio who sequence thousands of samples of varying inputs. The technology is positioned to drive NGS adoption in agricultural genomics, enabling streamlined, scalable, and cost-effective workflows for high-throughput applications in breeding, trait selection, and other research areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) reported record revenue of $71.5M in 1QFY24, a 32% increase over 1QFY23. Orders increased to $77.5M, a 19% increase over 1QFY23. The company raised its FY 2024 revenue guidance to $288M to $293M and increased FY 2024 gross margin guidance to 40% to 41%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.01%
Tags
-
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) has expanded its Twist Express Genes service to include larger DNA preparations, offering rapid gene synthesis at all gene prep scales, enabling large scale experimentation for pharmaceutical, biotechnology, academic, and industrial chemical researchers. The service has received positive feedback from customers for its consistent and rapid turnaround time. The company leverages its silicon-based DNA synthesis platform to deliver Clonal Genes and Gene Fragments at scale and with rapid turnaround times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.03%
Tags
none
Rhea-AI Summary
Twist Bioscience Corporation (NASDAQ: TWST) will issue its financial results for the fiscal 2024 first quarter on February 2, 2024. The company plans to hold a conference call and live audio webcast to discuss its financial results and provide an update on the company’s business. The press release with the financial results will be accessible from the company’s website. The conference call will be webcast live and the webcast replay will be available for two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences earnings

FAQ

What is the current stock price of Twist Bioscience (TWST)?

The current stock price of Twist Bioscience (TWST) is $39.18 as of March 6, 2025.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately 2.5B.

What does Twist Bioscience specialize in?

Twist Bioscience specializes in synthetic biology, focusing on industrial-scale production of synthetic DNA using a proprietary silicon-based platform.

How does Twist Bioscience's technology differ from traditional DNA synthesis methods?

Twist Bioscience uses a semiconductor-based platform with a 10,000-well silicon design, enabling faster, cost-effective, and high-throughput DNA synthesis compared to traditional 96-well plastic plates.

What industries benefit from Twist Bioscience's products?

Industries such as pharmaceuticals, personalized medicine, agriculture, sustainable chemical production, biodetection, and DNA data storage benefit from Twist Bioscience's synthetic DNA tools.

How does Twist Bioscience generate revenue?

Twist Bioscience generates revenue through direct sales of synthetic DNA products and services to biotech firms, pharmaceutical companies, and research organizations.

Who are Twist Bioscience's main competitors?

Twist Bioscience competes with companies like Ginkgo Bioworks, Codexis, and Integrated DNA Technologies in the synthetic biology and DNA synthesis markets.

What makes Twist Bioscience unique in the synthetic biology market?

Twist Bioscience's proprietary silicon-based DNA synthesis platform offers unmatched scalability, efficiency, and cost-effectiveness, setting it apart in the synthetic biology market.

What applications does Twist Bioscience's technology support?

Twist Bioscience's technology supports applications in pharmaceutical research, personalized medicine, agriculture, DNA data storage, biodetection, and sustainable chemical production.

Where does Twist Bioscience derive most of its revenue?

Twist Bioscience derives the majority of its revenue from customers based in the United States.
Twist Bioscience

Nasdaq:TWST

TWST Rankings

TWST Stock Data

2.51B
58.35M
1.94%
110.12%
15.4%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO